Diabetes Management with Basal Insulin Therapy

Introduction to Basal Insulin Options

Basal insulin options include NPH insulin, long-acting insulin analogs, and continuous delivery of rapid-acting insulin via an insulin pump, as recommended by the American Diabetes Association 1, 2

U-300 Glargine has a longer duration of action, a more stable 24-hour glucose-lowering profile, and a lower risk of nocturnal hypoglycemia compared to U-100 glargine, with slightly lower efficacy per unit 1
Insulin degludec and glargine U-300 have longer half-lives and durations of action, with more even distribution over 24 hours 3, 4
U-300 glargine has a longer duration of action than standard U-100 glargine, with modestly lower efficacy per unit administered compared to U-100 formulations 1, 5

Basal insulin therapy reduces the risk of symptomatic and nocturnal hypoglycemia, according to the American Diabetes Association 1, 2
Long-acting basal analogs, such as insulin degludec and glargine U-300, have demonstrated a reduced risk of symptomatic and nocturnal hypoglycemia compared with NPH insulin in clinical trials 3

The initial dose of basal insulin is typically 0.1-0.2 units/kg/day based on body weight and degree of hyperglycemia, as recommended by the American Diabetes Association 1, 2
Basal insulin dose should be titrated over days to weeks as needed based on fasting glucose readings, with caution for overbasalization signals such as basal dose >0.5 units/kg, high bedtime-morning glucose differential, hypoglycemia episodes, and high glucose variability 1, 2
When switching from insulin glargine to insulin degludec, the initial dose can be the same as the previous glargine dose, and it can be administered at any time of day, but should be consistent 3
For patients at high risk for hypoglycemia, consider an initial dose reduction of 10-20% when switching from other insulins to insulin glargine U-300 or from degludec to glargine U-300 3, 4, 1, 5

Basal insulin can be added to metformin and other oral agents or non-insulin injectables, according to the American Diabetes Association 1
For patients with type 1 diabetes, basal insulin is used in combination with mealtime insulin, as recommended by the American Diabetes Association 2
The American Diabetes Association and the European Association for the Study of Diabetes recognize that newer formulations of insulin, such as insulin degludec and insulin glargine U-300, offer a lower risk of nocturnal hypoglycemia compared to NPH insulin, due to their more stable 24-hour glucose-lowering profiles 3, 4, 1, 5

Insulin glargine products should be stored according to manufacturer recommendations, and should not be mixed with other insulins in the same syringe, as it may alter the time-action profile, and are not for intravenous use 6
Insulin detemir may require twice-daily dosing in some patients, as noted by the American Association of Clinical Endocrinologists 7

The World Health Organization recommends human insulin as first-line for managing blood glucose in adults with type 1 and type 2 diabetes (strong recommendation) and suggests long-acting insulin analogs for adults with frequent severe hypoglycemia with human insulin (weak recommendation) 8
The American Diabetes Association and the European Association for the Study of Diabetes support the use of insulin glargine for type 1 and type 2 diabetes management, with consideration of the pharmacokinetic profile when selecting a long-acting insulin 1, 7, 4